BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.

Pan- or multidrug resistance is a central problem in clinical oncology. Here, we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP inhibition. We found that multidrug resistance was strongly associated with an EMT-like sarcomatoid phenotype and high expression of the Abcb1b gene, which encodes the drug efflux transporter P-glycoprotein. Inhibition of P-glycoprotein could partly resensitize sarcomatoid tumors to the PARP inhibitor olaparib, docetaxel, and doxorubicin. We propose that multidrug resistance is a multifactorial process and that mouse models are useful to unravel this.

[1]  Andreas Schlicker,et al.  Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition , 2013, International journal of cancer.

[2]  S. Rodenhuis,et al.  Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy , 2014, Breast Cancer Research.

[3]  Jacques Neefjes,et al.  Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin , 2013, Nature Communications.

[4]  Jean-Pierre Gillet,et al.  The clinical relevance of cancer cell lines. , 2013, Journal of the National Cancer Institute.

[5]  R. Tavares,et al.  Claudin Expression in High Grade Invasive Ductal Carcinoma of the Breast: Correlation with the Molecular Subtype , 2012, Modern Pathology.

[6]  Shridar Ganesan,et al.  Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. , 2013, Cancer discovery.

[7]  R. Bernards,et al.  MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling , 2012, Cell.

[8]  Massimo Broggini,et al.  Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. , 2012, Cancer treatment reviews.

[9]  P. Borst.  Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? , 2012, Open Biology.

[10]  S. Bates,et al.  Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[11]  M. Gottesman,et al.  Response of BRCA 1-Deficient Mammary Tumors Impact of Intertumoral Heterogeneity on Predicting Chemotherapy , 2012 .

[12]  Min Zhu,et al.  Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage , 2011, Genome Biology.

[13]  Syed Haider,et al.  Ensembl BioMarts: a hub for data retrieval across taxonomic space , 2011, Database J. Biol. Databases Curation.

[14]  A. Rangarajan,et al.  Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters , 2011, Cell Death and Disease.

[15]  M. J. van de Vijver,et al.  Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Wesseling,et al.  Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice , 2011, Disease Models & Mechanisms.

[17]  K. Gelmon,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[18]  Hongli Li,et al.  Overexpression of Snail accelerates adriamycin induction of multidrug resistance in breast cancer cells. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[19]  H. Putter,et al.  Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor–positive early breast cancer patients , 2011, Breast Cancer Research and Treatment.

[20]  Yuzhuo Wang,et al.  Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts , 2010, Clinical Cancer Research.

[21]  A. Ashworth,et al.  Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation , 2010, British Journal of Cancer.

[22]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[23]  L. Wessels,et al.  Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers , 2010, BMC Cancer.

[24]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[25]  A. Ashworth,et al.  Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas , 2010, The Journal of pathology.

[26]  M. Pajic,et al.  Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. , 2010, Cancer research.

[27]  Byung-Ho Nam,et al.  Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer , 2010, Breast Cancer Research and Treatment.

[28]  Hui Wang,et al.  Multidrug resistance in breast cancer cells during epithelial-mesenchymal transition is modulated by breast cancer resistant protein. , 2010, Chinese journal of cancer.

[29]  Hideo Baba,et al.  Epithelial–mesenchymal transition in cancer development and its clinical significance , 2010, Cancer science.

[30]  D. Adams,et al.  A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors , 2009, Clinical Cancer Research.

[31]  J. Klijn,et al.  Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[33]  Nicholas J. Wang,et al.  Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.

[34]  A. Lau,et al.  Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. , 2009, Cancer research.

[35]  Wen-juan Wang,et al.  Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer Cells , 2009, Clinical Cancer Research.

[36]  D. Miles,et al.  Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study. , 2009 .

[37]  B. Kreike,et al.  Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis , 2009, Breast Cancer Research and Treatment.

[38]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[39]  W. Richard McCombie,et al.  Topoisomerase levels determine chemotherapy response in vitro and in vivo , 2008, Proceedings of the National Academy of Sciences.

[40]  A. Lau,et al.  Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin , 2008, Clinical Cancer Research.

[41]  Jos Jonkers,et al.  Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer , 2007, Proceedings of the National Academy of Sciences.

[42]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[43]  T. Fojo,et al.  Characterization of Gene Rearrangements Leading to Activation of MDR-1*> , 2006, Journal of Biological Chemistry.

[44]  Jos Jonkers,et al.  Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. , 2006, Cancer cell.

[45]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[46]  Robert D Cardiff,et al.  The transcriptional repressor Snail promotes mammary tumor recurrence. , 2005, Cancer cell.

[47]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[48]  D. Zwijnenburg,et al.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.

[49]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[50]  M. J. van de Vijver,et al.  Determining MDR1/P‐glycoprotein expression in breast cancer , 2001, International journal of cancer.

[51]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[52]  J. Schellens,et al.  Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. , 1999, Cancer research.

[53]  D. Scherman,et al.  Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. , 1994, Biochemical pharmacology.